SecBot SecBot
SC 13G/A ·Filed Nov 13, 2026

VNDA

Vanda Pharmaceuticals Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3d 18h ago SEC0001167557-26-000261
Passive stake amendment
Actionable Insight • Neutral

AQR's reduction to below 5% removes the need for future 13G filings, but the passive nature and small stake size limit any signal. Monitor for any further institutional trimming or conversion to 13D by other holders.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$3.99
T+0 close · Nov 13, 2026 · via day close
Latest settled
−4.51%
T+1 · $3.81
Vs SPY
−2.60%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $3.99entry
  2. T+1 · 20h ago −4.51%α −2.60% · $3.81
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AQR Capital Management filed an amended Schedule 13G disclosing a 3.47% passive stake in Vanda Pharmaceuticals as of September 30, 2026, down from a prior filing that did not specify a percentage. The reduction in stake suggests AQR has trimmed its position, though the filing remains passive with no activist intent.

Key Financial Metrics

Stake
3.47%
Investor
AQR Capital Management LLC
Investor Type
hedge fund

Key Facts

  • AQR Capital Management disclosed a 3.47% passive stake in Vanda Pharmaceuticals as of September 30, 2026
  • AQR holds 2,096,939 shares of common stock
  • This is an amendment to a prior Schedule 13G filing, indicating a reduction from a previously undisclosed higher stake
  • The filing is passive under Rule 13d-1(b), with no activist intent

Financial Impact

AQR's stake reduced to 3.47% from a previously undisclosed level; no dollar value stated

ownership

Risk Factors

  • AQR's reduction could signal waning institutional conviction, though the stake remains material at 3.47%
  • No specific reason for the reduction is provided in the filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0001167557-26-000261
Document: 0001167557-26-000261-index.html0001167557-26-000261
Document: 0001167557-26-000261.txt0001167557-26-000261

Track record

8 reports on VNDA

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Viewing Entry $3.99 Now $3.81 −4.51% settles Nov 20
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.08 Now $3.81 −6.62% settles Nov 17
  3. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $4.05 to $3.59 Now $3.81 −5.93% ▼ −11.36% −6.63% vs SPY
  4. Oct 27, 202620d ago SC 13G Neutral 4/10 Entry $4.00 to $3.88 Now $3.81 −4.75% ▼ −3.00% −2.29% vs SPY
  5. Oct 21, 202626d ago Press Release Neutral 1/10 Entry $4.05 to $4.05 Now $3.81 −5.93% · 0.00% −0.71% vs SPY
  6. Oct 9, 20265w ago SC 13G/A Neutral 4/10 Entry $4.54 to $4.09 Now $3.81 −16.08% ▼ −9.91% −8.42% vs SPY
  7. Jul 29, 202615w ago Press Release Neutral 1/10 Entry $5.18 Now $3.81 −26.45% No price data
  8. May 6, 202627w ago 8-K Mixed 6/10 Entry $6.39 to $6.43 Now $3.81 −40.38% ▲ +0.63% −0.88% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 6h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026